, Volume 73, Issue 8, pp 803–814 | Cite as

Optimizing the Use of Aspirin for Cardiovascular Prevention

  • Rubén Casado-Arroyo
  • Carlos Sostres
  • Angel Lanas
Review Article


This article describes the mechanism of action, pharmacokinetics, and pharmacodynamics of aspirin at doses used for cardiovascular prevention and provides specific management recommendations for optimal use in clinical practice. The paper highlights practical aspects related to antiplatelet therapy, including the optimal dose of aspirin, concomitant treatment with other NSAIDs, and strategies for the prevention of gastrointestinal toxicity. Specifically, we revise the benefits and hazards in different clinical settings to help the clinician in the decision-making process for individuals who have different risks for cardiovascular and gastrointestinal bleeding events.


Aspirin Acute Coronary Syndrome Clopidogrel Antiplatelet Agent Pylorus Eradication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was funded by a grant for international research post-residency, Spanish Society of Cardiology (RC); B01 from the Regional Government of Aragón in Spain (AL).


  1. 1.
    World Health Organization. 2013. Accessed 9 May 2013.
  2. 2.
    Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:49–59.CrossRefGoogle Scholar
  3. 3.
    Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849.PubMedCrossRefGoogle Scholar
  4. 4.
    Casado-Arroyo R, Bayrak F, Sarkozy A, Chierchia GB, de Asmundis C, Brugada P. Role of ASA in the primary and secondary prevention of cardiovascular events. Best Pract Res Clin Gastroenterol. 2012;26(2):113–23.PubMedCrossRefGoogle Scholar
  5. 5.
    US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396–404.CrossRefGoogle Scholar
  6. 6.
    Casado-Arroyo R, Gargallo C, Lanas Arbeloa A. Balancing the risk and benefits of low-dose aspirin in clinical practice. Best Pract Res Clin Gastroenterol. 2012;26(2):173–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366–72.PubMedCrossRefGoogle Scholar
  8. 8.
    FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676–88.PubMedCrossRefGoogle Scholar
  9. 9.
    Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995;2:637–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Catella F, Davì G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA, American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e637S–68S.Google Scholar
  13. 13.
    Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71–86.CrossRefGoogle Scholar
  14. 14.
    Farrel B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–54.CrossRefGoogle Scholar
  15. 15.
    The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261–6.CrossRefGoogle Scholar
  16. 16.
    Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation. 2010;121:1455–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295–301.PubMedCrossRefGoogle Scholar
  18. 18.
    Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293.PubMedCrossRefGoogle Scholar
  19. 19.
    Anzellotti P, Capone ML, Jeyam A, Tacconelli S, Bruno A, Tontodonati P, Di Francesco L, Grossi L, Renda G, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum. 2011;63:850–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D’Amelio E, Zurro M, Price TS, Patrono C, De Caterina R, Patrignani P. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006;80:264–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755.PubMedCrossRefGoogle Scholar
  22. 22.
    de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89.PubMedCrossRefGoogle Scholar
  23. 23.
    Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patients data from randomised trials. Lancet. 2011;377:31–41.PubMedCrossRefGoogle Scholar
  24. 24.
    International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569–81.Google Scholar
  25. 25.
    CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebocontrolled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349:1641–49.Google Scholar
  26. 26.
    Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71–86.Google Scholar
  27. 27.
    The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233.Google Scholar
  28. 28.
    Peters RJG, Mehta SR, Fox KAA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672–84.PubMedCrossRefGoogle Scholar
  30. 30.
    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–164.Google Scholar
  32. 32.
    Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf. 2011;10(1):45–54.PubMedCrossRefGoogle Scholar
  33. 33.
    Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795–801.PubMedCrossRefGoogle Scholar
  34. 34.
    Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012;156(1):69–75.PubMedCrossRefGoogle Scholar
  35. 35.
    Sud A, Kline-Rogers EM, Eagle KA, Fang J, Armstrong DF, Rangarajan K, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother. 2005;39:1792–7.PubMedCrossRefGoogle Scholar
  36. 36.
    García Rodríguez LA, Cea Soriano L, Martín-Merino E, Johansson S. Discontinuation of low-dose acetylsalicylic acid treatment for secondary prevention of cardiovascular outcomes. Circulation. 2009;120:S480.Google Scholar
  37. 37.
    Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667–74.PubMedCrossRefGoogle Scholar
  39. 39.
    García Rodríguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011;76(8):740–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Yeomans ND. Aspirin: old drug, new uses and challenges. J Gastroenterol Hepatol. 2011;26(3):426–31.PubMedCrossRefGoogle Scholar
  41. 41.
    Simon B, Elsner H, Muller P. Protective effect of omeprazol against low dose acetylsalicylic acid. Endoscopic controlled double-blind study in healthy subjects. Arzneimittelforshung. 1995;45:701–3.Google Scholar
  42. 42.
    Muller P, Fuchs W, Simon B. Studies on protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic. An endoscopic controlled double-blind study. Arzneimittelforshung. 1997;47:758–60.Google Scholar
  43. 43.
    Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a doubleblind trial. Gastroenterology. 2004;127(2):395–402.PubMedCrossRefGoogle Scholar
  44. 44.
    Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9(9):762–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;20(4):22.CrossRefGoogle Scholar
  46. 46.
    Taha AS, Angerson WJ, Prasad R, McCloskey C, Gilmour D, Morran CG. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;28(7):878–85.PubMedGoogle Scholar
  47. 47.
    Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005;100:1685–93.PubMedCrossRefGoogle Scholar
  48. 48.
    Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2005;21:169–75.PubMedCrossRefGoogle Scholar
  49. 49.
    Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008;135:1517–25.PubMedCrossRefGoogle Scholar
  50. 50.
    Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther. 2008;10(1):R7.Google Scholar
  51. 51.
    Smecuol E, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol. 2009;2009(7):524–9.CrossRefGoogle Scholar
  52. 52.
    Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology. 2011;140(5):1427–33.Google Scholar
  53. 53.
    Chan FK. Review: low-dose aspirin causes a small increase in gastrointestinal bleeding. ACP J Club. 2007;146:13.PubMedGoogle Scholar
  54. 54.
    Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449–61.PubMedCrossRefGoogle Scholar
  55. 55.
    Moukarbel GV, Signorovitch JE, Pfeffer MA, et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J. 2009;30:2226–32.PubMedCrossRefGoogle Scholar
  56. 56.
    Shiotani A, Sakakibara T, Nomura M, Yamanaka Y, Nishi R, Imamura H, et al. Aspirin-induced peptic ulcer and genetic polymorphisms. J Gastroenterol Hepatol. 2010;25(Suppl 1):S31–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Casado Arroyo R, Polo-Tomas M, Roncalés MP, Scheiman J, Lanas A. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart. 2012;98(9):718–23.PubMedCrossRefGoogle Scholar
  58. 58.
    Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics. 2006;24:155–69.PubMedCrossRefGoogle Scholar
  59. 59.
    Pignone M, Earnshaw S, Tice JA, Pletcher MJ. US proved aspirin therapy to be cost-saving compared with no aspirin in males older than 45 years old when the 10-year risk of developing cardiovascular disease was >7.5%. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326–36.PubMedCrossRefGoogle Scholar
  60. 60.
    Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Ann Intern Med. 2007;167:290–5.CrossRefGoogle Scholar
  61. 61.
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.Google Scholar
  62. 62.
    Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E, CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89.Google Scholar
  63. 63.
    Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–21.Google Scholar
  64. 64.
    Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, Gabriel S, Yusuf S, CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005;45(6):838–45.Google Scholar
  65. 65.
    Lamy A, Jönsson B, Weintraub WS, Zhao F, Chrolavicius S, Bakhai A, Culler S, Gafni A, Lindgren P, Mahoney E, Yusuf S, CURE Economic Group. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil. 2004;11(6):460–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Mahoney EM, Mehta S, Yuan Y, Jackson J, Chen R, Gabriel S, Lamy A, Culler S, Caro J, Yusuf S, Weintraub WS, CURE Study Investigators. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J. 2006;151(1):219–27.PubMedCrossRefGoogle Scholar
  67. 67.
    Gibler KB, Huskamp HA, Sabatine MS, Murphy SA, Cohen DJ, Cannon CP. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. Crit Pathw Cardiol. 2010;9(1):14–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction TRITON-TIMI 38. Circulation. 2010;121(1):71–9.PubMedCrossRefGoogle Scholar
  69. 69.
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.CrossRefGoogle Scholar
  70. 70.
    Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med. 2004;116(12):797–806.PubMedCrossRefGoogle Scholar
  71. 71.
    de Groot NL, van Haalen HG, Spiegel BM, Laine L, Lanas A, Focks JJ, Siersema PD, van Oijen MG. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance. Cardiovasc Drugs Ther. 2013 (in press).Google Scholar
  72. 72.
    Cohen MM, MacDonald WC. Mechanism of aspirin injury to human gastroduodenal mucosa. Prostaglandins Leukot Med. 1982;9(2):241–55.PubMedCrossRefGoogle Scholar
  73. 73.
    Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502–17.PubMedCrossRefGoogle Scholar
  74. 74.
    Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, Sung JJ. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344(13):967–73.PubMedCrossRefGoogle Scholar
  75. 75.
    Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO, Lai CL, Wong J. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32(7):831–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144(3):528–35.Google Scholar
  78. 78.
    Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352(3):238–44.PubMedCrossRefGoogle Scholar
  79. 79.
    Ibáñez L, Vidal X, Vendrell L, Moretti U, Laporte JR, Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23:235–42.PubMedCrossRefGoogle Scholar
  80. 80.
    Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, Zapata E, Bástida G, Rodrigo L, Santolaria S, Güell M, de Argila CM, Quintero E, Borda F, Piqué JM. Risk of upper gastrointestinal ulcer bleeding associated with selective COX 2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut. 2006;55:1731–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60(7):645–81.PubMedCrossRefGoogle Scholar
  82. 82.
    Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.PubMedCrossRefGoogle Scholar
  83. 83.
    Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, Chan FK. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152(1):1–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Sung JJ, Tsoi KK, Ma TK, Yung MY, Lau JY, Chiu PW. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol. 2010;105(1):84–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, Perez-Gisbert J, Bujanda L, Castro M, Muñoz M, Rodrigo L, Calvet X, Del-Pino D, Garcia S. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104(7):1633–41.PubMedCrossRefGoogle Scholar
  86. 86.
    Lanas A, Polo-Tomás M, Casado-Arroyo R. The aspirin cardiovascular/gastrointestinal risk calculator–a tool to aid clinicians in practice. Aliment Pharmacol Ther. 2013;37(7):738–48.PubMedCrossRefGoogle Scholar
  87. 87.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMedCrossRefGoogle Scholar
  88. 88.
    Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Rubén Casado-Arroyo
    • 2
    • 3
  • Carlos Sostres
    • 1
  • Angel Lanas
    • 1
  1. 1.Service of Digestive Diseases, University Hospital Lozano BlesaUniversity of Zaragoza, IIS Aragón, CIBERehdZaragozaSpain
  2. 2.Heart Rhythm Management Center, Cardiovascular Division, Cardiovascular CenterFree University of Brussels (UZ Brussels) VUBBrusselsBelgium
  3. 3.Service of Cardiology, University Hospital Lozano BlesaUniversity of Zaragoza, IIS Aragon, CIBERehdZaragozaSpain

Personalised recommendations